Relmada Therapeutics, Inc. (RLMD)
4.52
+0.45
(+11.06%)
USD |
NASDAQ |
Sep 11, 16:00
4.62
+0.10
(+2.21%)
After-Hours: 20:00
Relmada Therapeutics Enterprise Value : 264.42M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 264.42M |
| September 10, 2026 | 216.41M |
| September 09, 2026 | 218.55M |
| September 08, 2026 | 235.62M |
| September 04, 2026 | 254.82M |
| September 03, 2026 | 248.42M |
| September 02, 2026 | 266.55M |
| September 01, 2026 | 258.02M |
| August 31, 2026 | 247.35M |
| August 28, 2026 | 244.15M |
| August 27, 2026 | 264.42M |
| August 26, 2026 | 267.62M |
| August 25, 2026 | 271.88M |
| August 24, 2026 | 270.82M |
| August 21, 2026 | 276.15M |
| August 20, 2026 | 277.22M |
| August 19, 2026 | 297.48M |
| August 18, 2026 | 299.62M |
| August 17, 2026 | 291.08M |
| August 14, 2026 | 294.28M |
| August 13, 2026 | 288.95M |
| August 12, 2026 | 285.75M |
| August 11, 2026 | 259.08M |
| August 10, 2026 | 266.55M |
| August 07, 2026 | 309.22M |
| Date | Value |
|---|---|
| August 06, 2026 | 355.09M |
| August 05, 2026 | 362.55M |
| August 04, 2026 | 365.75M |
| August 03, 2026 | 347.62M |
| July 31, 2026 | 348.69M |
| July 30, 2026 | 352.95M |
| July 29, 2026 | 330.55M |
| July 28, 2026 | 340.15M |
| July 27, 2026 | 336.95M |
| July 24, 2026 | 334.82M |
| July 23, 2026 | 336.95M |
| July 22, 2026 | 315.62M |
| July 21, 2026 | 347.62M |
| July 20, 2026 | 315.62M |
| July 17, 2026 | 341.22M |
| July 16, 2026 | 364.69M |
| July 15, 2026 | 444.69M |
| July 14, 2026 | 444.69M |
| July 13, 2026 | 470.29M |
| July 10, 2026 | 466.02M |
| July 09, 2026 | 476.69M |
| July 08, 2026 | 466.02M |
| July 07, 2026 | 466.02M |
| July 06, 2026 | 457.49M |
| July 02, 2026 | 452.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.847B |
| Corcept Therapeutics, Inc. | 11.87B |
| Veru, Inc. | 18.49M |
| Johnson & Johnson | 667.86B |
| Eli Lilly & Co. | 1.096T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.91M |
| Total Expenses (Quarterly) | 12.91M |
| EPS Diluted (Quarterly) | -0.1149 |
| Earnings Yield | -20.58% |
| Normalized Earnings Yield | -20.53 |